#abbvie

DataScienceJobsdatasciencejobs
2025-08-13

🏢 AbbVie is hiring a Data Science Program Lead II
Location: 🇺🇸 North Chicago, Illinois, United States

datasciencejobs.com/jobs/data-

Terviralterviral
2025-07-30

AbbVie (ABBV)

- (ABBV) hari ini untuk membantu sebelum memulai dan saham AbbVie . AbbVie Inc. (NYSE: ABBV) adalah global yang berfokus pada dan obat-obatan , terutama di bidang , onkologi, neurosains, dan virologi. Perusahaan ini terkenal berkat obat Humira, salah satu obat terlaris di dunia untuk penyakit autoimun…

tradingan.com/abbvie

News24medianews24media
2025-07-11

Glenmark hits ₹2,094/share after sealing a $2 billion global drug licensing deal with AbbVie! 🌍💰
Is India’s biotech game finally going global?
Tap for full market analysis + chart breakdown!

news24media.org/glenmark-share

Zougla.grzougla
2025-07-08

AbbVie και «ΑΝΑΣΑ» δίνουν ανάσα αισιοδοξίας και αλληλεγγύης στην κοινωνία zougla.gr/ygeia/farmako-nea/ab

DataScienceJobsdatasciencejobs
2025-07-07

💼 AbbVie is hiring a Data Science Program Lead III
Location: 🇺🇸 North Chicago, Illinois, United States

datasciencejobs.com/jobs/data-

Zougla.grzougla
2025-07-04

Α’ Αντιπρόεδρος του Ελληνο-Αμερικανικού Εμπορικού Επιμελητηρίου η πρόεδρος και διευθύνουσα σύμβουλος της AbbVie, Λαμπρίνα Μπαρμπετάκη  zougla.gr/ygeia/farmako-nea/a-

Yonhap Infomax Newsinfomaxkorea
2025-06-23

CNBC spotlights five dividend stocks—including AbbVie and Coca-Cola—as investor interest shifts to stable income plays amid ongoing market and economic uncertainty.

en.infomaxai.com/news/articleV

DataScienceJobsdatasciencejobs
2025-05-12

💼 AbbVie is hiring a Senior Data Scientist
Location: 🇺🇸 Mettawa, Illinois, United States

datasciencejobs.com/jobs/senio

Yonhap Infomax Newsinfomaxkorea
2025-05-02

MAI Capital recommends AbbVie and UnitedHealth as resilient healthcare stocks in unstable market, while advising caution on Booking Holdings amid potential recession.

en.infomaxai.com/news/articleV

Yonhap Infomax Newsinfomaxkorea
2025-04-30

Microsoft's stock decline deemed unwarranted by analyst, who highlights company's solid business performance and growth potential amid tech sector volatility

en.infomaxai.com/news/articleV

Don Curren 🇨🇦🇺🇦dbcurren.bsky.social@bsky.brid.gy
2025-04-25

Bloomberg: #Alphabet #shares rally 6% in early trading as the company's strength in #search #advertising helped profit beat estimates. #AbbVie, #Colgate-Palmolive and #Schlumberger are slated to report later. #Stocks and the dollar edge higher. #markets

DataScienceJobsdatasciencejobs
2025-04-16

🏢 AbbVie is hiring an Associate Director, Data Science (Indirect Procurement)
Location: 🇺🇸 North Chicago, Illinois, United States

datasciencejobs.com/jobs/assoc

Yonhap Infomax Newsinfomaxkorea
2025-04-02

US pharmaceutical giants face potential tariff risks as Trump administration considers imposing up to 25% tariffs on imported drugs, with Merck, AbbVie, Amgen, and Pfizer identified as most vulnerable.

en.infomaxai.com/news/articleV

DataScienceJobsdatasciencejobs
2025-03-25

🏢 AbbVie is hiring an Associate Director, Procurement Data Science (Direct Procurement)
Location: 🇺🇸 North Chicago, Illinois, United States

datasciencejobs.com/jobs/assoc

Yonhap Infomax Newsinfomaxkorea
2025-03-17

Dividend-focused ETF SCHD gains attention as New York stock market correction increases its yield, offering attractive investment opportunity amid market volatility

en.infomaxai.com/news/articleV

Rundkuchenbrot / PseudoRundkuchenbrot@troet.cafe
2025-03-02

Migränepatienten steht eine neue Wirkstoffklasse an Prophylaxemedikamenten zur Verfügung
Mit dem Präparat #Aquipta #atogepant bringt US-Hersteller #Abbvie am 1. März erstmals ein Mittel aus der Substanzklasse der #Gepante

Aquipta ist zugelassen zur #Migräneprophylaxe bei erwachsenen Patientinnen und Patienten mit 4 oder mehr Migränetagen pro Monat. Es kann sowohl bei episodischer als auch bei chronischer #Migräne verschrieben werden.
- einmal täglich als Tablette ein

aerzteblatt.de/news/gepante-ne

Stocklestockle
2025-01-31

$ABBV AbbVie Inc Q4 - Raises outlook for immunology drugs💊

EPS: $2.16 (Est. $2.12)
Revenue: $15.10B +5.6% (Est. $14.83B)

"We are entering 2025 with significant momentum and expect net revenues to exceed their previous peak” - Rob Michael, CEO

📈+8%

Client Info

Server: https://mastodon.social
Version: 2025.07
Repository: https://github.com/cyevgeniy/lmst